Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Mikael Cohen"'
Autor:
Hélène Bartak, Tasnim Fareh, Nouha Ben Othman, Delphine Viard, Mikael Cohen, Fanny Rocher, Elliot Ewig, Milou-Daniel Drici, Christine Lebrun-Frenay
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 917-930 (2024)
Abstract Introduction Over the past few years, anti-CD20 therapies like rituximab, ocrelizumab or ofatumumab have seen an increase in interest in the treatment of neurological autoimmune disorders such as multiple sclerosis (MS), neuromyelitis optica
Externí odkaz:
https://doaj.org/article/68c221405b3a4e8c8d9ce0e267db9995
Autor:
Cassandre Landes‐Chateau, Michael Levraut, Darin T. Okuda, Albert Themelin, Mikael Cohen, Orhun H. Kantarci, Aksel Siva, Daniel Pelletier, Lydiane Mondot, Christine Lebrun‐Frenay, on behalf RISConsortium
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 3, Pp 662-672 (2024)
Abstract Objective The radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS). Increasing evidence suggests that the central vein sign (CVS) enhances lesion specificity, allowing for gre
Externí odkaz:
https://doaj.org/article/9abdd644db594616ba70706ce0752b3c
Autor:
Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer
Publikováno v:
Neurology and Therapy, Vol 12, Iss 2, Pp 529-542 (2023)
Abstract Introduction Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended i
Externí odkaz:
https://doaj.org/article/7ab6cfd0c28d47328cdce3b6dc0d39a9
Autor:
Stanislas Demuth, Maxime Guillaume, Bertrand Bourre, Jonathan Ciron, Hélène Zephir, Yoann Sirejacob, Anne Kerbrat, Christine Lebrun-Frenay, Caroline Papeix, Laure Michel, David Laplaud, Sandra Vukusic, Elisabeth Maillart, Mikael Cohen, Bertrand Audoin, Romain Marignier, Nicolas Collongues, for the NOMADMUS Study Group
Publikováno v:
Journal of Neuroinflammation, Vol 19, Iss 1, Pp 1-12 (2022)
Abstract Background Neuromyelitis optica spectrum disorder (NMOSD) attacks require an urgent probabilistic anti-inflammatory therapeutic strategy. As inadequately treated attacks result in disability, there is a need to identify the optimal attack-tr
Externí odkaz:
https://doaj.org/article/3303f869769e4e088b82a23e81200da9
Autor:
Jonathan Giovannelli, Jonathan Ciron, Mikael Cohen, Ho‐Jin Kim, Su‐Hyun Kim, Jan‐Patrik Stellmann, Ingo Kleiter, Morgan McCreary, Benjamin M. Greenberg, Romain Deschamps, Bertrand Audoin, Elisabeth Maillart, Caroline Papeix, Nicolas Collongues, Bertrand Bourre, David Laplaud, Xavier Ayrignac, Françoise Durand‐Dubief, Aurélie Ruet, Sandra Vukusic, Romain Marignier, Luc Dauchet, Hélène Zephir, NEMOS (Neuromyelitis Optica Study Group in Germany), NOMADMUS (Neuromyelitis Optica study Group in France), OFSEP (Observatoire Français de la Sclérose en Plaques) investigators
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 10, Pp 2025-2037 (2021)
Abstract Objective As phase III trials have shown interest in innovative but expensive drugs in the treatment of neuromyelitis optica spectrum disorder (NMOSD), data are needed to clarify strategies in the treatment of neuromyelitis optica (NMO). Thi
Externí odkaz:
https://doaj.org/article/4753bf99349c42148b275b370e2f8adf
Autor:
Michael Levraut, Cassandre Landes, Lydiane Mondot, Mikael Cohen, Saskia Bresch, Vesna Brglez, Barbara Seitz-Polski, Christine Lebrun-Frenay
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionMany patients are referred to multiple sclerosis (MS) tertiary centers to manage brain white matter hyperintensities (WMH). Multiple diagnoses can match in such situations, and we lack proper tools to diagnose complex cases.ObjectiveThis
Externí odkaz:
https://doaj.org/article/ce29dafb5f9d460caad6d003c57c9c84
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 599-604 (2020)
Abstract Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine’s me
Externí odkaz:
https://doaj.org/article/3a4d0e9ba16447ef8b9c635ab345a3b9
Autor:
Elisabeth Maillart, Françoise Durand-Dubief, Céline Louapre, Bertrand Audoin, Bertrand Bourre, Nathalie Derache, Jonathan Ciron, Nicolas Collongues, Jérome de Sèze, Mikael Cohen, Christine Lebrun-Frenay, Nawel Hadhoum, Hélène Zéphir, Romain Deschamps, Clarisse Carra-Dallière, Pierre Labauge, Philippe Kerschen, Alexis Montcuquet, Sandrine Wiertlewski, David Laplaud, Gwenaëlle Runavot, Sandra Vukusic, Caroline Papeix, Romain Marignier, on behalf of the OFSEP, SFSEP, and NOMADMUS study groups
Publikováno v:
Journal of Neuroinflammation, Vol 17, Iss 1, Pp 1-8 (2020)
Abstract Background Longitudinally extensive transverse myelitis (LETM) is classically related to aquaporin (AQP4)-antibodies (Ab) neuromyelitis optica spectrum disorders (NMOSD) or more recently to myelin oligodendrocyte glycoprotein (MOG)-Ab associ
Externí odkaz:
https://doaj.org/article/586d33a918c24934a16a086211356b78
Autor:
Alvaro Cobo-Calvo, María Sepúlveda, Fabien Rollot, Thais Armangué, Anne Ruiz, Elisabeth Maillart, Caroline Papeix, Bertrand Audoin, Helene Zephir, Damien Biotti, Jonathan Ciron, Francoise Durand-Dubief, Nicolas Collongues, Xavier Ayrignac, Pierre Labauge, Eric Thouvenot, Bertrand Bourre, Alexis Montcuquet, Mikael Cohen, Romain Deschamps, Nuria Solà-Valls, Sara Llufriu, Jerome De Seze, Yolanda Blanco, Sandra Vukusic, Albert Saiz, Romain Marignier
Publikováno v:
Journal of Neuroinflammation, Vol 16, Iss 1, Pp 1-12 (2019)
Abstract Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeut
Externí odkaz:
https://doaj.org/article/ba4f3c78d68b4d88bfcba266552743c4
Autor:
Bruno Brochet, Mathilde S A Deloire, Paul Perez, Timothé Loock, Louise Baschet, Marc Debouverie, Sophie Pittion, Jean-Christophe Ouallet, Pierre Clavelou, Jérôme de Sèze, Nicolas Collongues, Patrick Vermersch, Hélène Zéphir, Giovanni Castelnovo, Pierre Labauge, Christine Lebrun, Mikael Cohen, Aurélie Ruet, PROMESS study investigators
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0168834 (2017)
Therapeutic options are limited in secondary progressive multiple sclerosis (SPMS). Open-label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction for delaying progression but no randomized trial was conducted so far.To
Externí odkaz:
https://doaj.org/article/f867f7bfcfbf41d68e3062cc711bb937